REG - BkofA Merrill Lynch AbbVie Inc. - Form 38.5(b) - AbbVie Inc

AbbvieAnnouncement

16/04/2020 11:05

RNS Number : 8791J
  
Bank of America Merrill Lynch
  
16 April 2020
  
 


FORM 38.5(b)
 
IRISH TAKEOVER PANEL



DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2013



DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT

RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED INTERMEDIARY

STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY 
 




1.


KEY INFORMATION










Name of exempt principal trader 






Bank of America, N.A., Proprietary







Company dealt in 






AbbVie Inc







Class of relevant security to which the

dealings being disclosed relate(Note 1) 






Common - US00287Y1091







Date of dealing 






09/04/2020



 




2.


INTERESTS AND SHORT POSITIONS









(a)


Interests and short positions (following dealing) in the class of relevant security

dealt in (Note 2) 







Class of relevant security: Common


US00287Y1091








Long


Short




Number


%


Number


%







(1) 


Relevant securities 






1,688,022


0.114% 


2,738,053


0.185 % 







(2) 


Derivatives (other than options): 






3,685,147


0.25% 


2,586,377


0.175% 







(3) 


Options and agreements to purchase/sell: 






0


0% 


0


0% 




Total


5,373,169


0.364% 


5,324,430


0.361% 



 




(b)


Interests and short positions in relevant securities of the company, other than the

class dealt in (Note 2) 








Class of relevant security: 












Long


Short




Number


%


Number


%







(1) 


Relevant securities 






0 


0% 


0 


0% 







(2) 


Derivatives (other than options): 






0 


0% 


0 


0% 







(3) 


Options and agreements to purchase/sell: 






0 


0% 


0 


0% 




Total


0 


0% 


0 


0% 








3.


DEALINGS (Note 3)








(a)


Purchases and sales







Purchase/sale


Number of relevant securities


Price per unit (Note 4) 




Purchase 


  422,443 


78.56 USD         




 Purchase 


        429 


79.74 USD         




 Purchase 


        100 


79.7 USD         




 Purchase 


     1,534 


79.75 USD         




 Purchase 


          19 


79.73 USD         



 



Purchase/sale


Number of relevant securities


Price per unit (Note 4) 




Sale 


  422,479 


78.56 USD         




 Sale 


          56 


79.23 USD         




 Sale 


          28 


79.42 USD         




 Sale 


          37 


79.16 USD         




 Sale 


          26 


79.21 USD         




 Sale 


          25 


79.07 USD         




 Sale 


          24 


78.84 USD         




 Sale 


          50 


78.86 USD         




 Sale 


          24 


79.15 USD         




 Sale 


          55 


79.19 USD         




 Sale 


          61 


79.14 USD         




 Sale 


          26 


79.17 USD         




 Sale 


          27 


79.11 USD         




 Sale 


          32 


79.03 USD         




 Sale 


          27 


79.32 USD         




 Sale 


          28 


79.37 USD         




 Sale 


          26 


79.34 USD         




 Sale 


          54 


79.4 USD         




 Sale 


          24 


79.52 USD         




 Sale 


          29 


79.59 USD         




 Sale 


          26 


79.27 USD         




 Sale 


          31 


79.31 USD         




 Sale 


          38 


79.5 USD         




 Sale 


          39 


79.6 USD         




 Sale 


          27 


79.8 USD         




 Sale 


          24 


79.81 USD         




 Sale 


     4,338 


79.75 USD         



 




(b)


Derivatives transactions (other than options transactions) 








Product name,

e.g. CFD 


Nature of transaction

(Note 5)


Number of relevant securities
(Note 6)


Price per unit

(Note 4)




Swaps


Closing a Long Position


363,261


78.56 USD




Swaps


Opening a Short Position


58,338


78.56 USD



 




(c)


Options transactions in respect of existing relevant securities 








(i)


Writing, selling, purchasing or varying







Product name, e.g. call option


Writing, selling, purchasing, varying etc.


Number of securities to which the option relates (Note 7)


Exercise price


Type, e.g. American, European etc


Expiry date


Option money paid/ received per unit (Note 4)




N/A


N/A


N/A


N/A


N/A


N/A


N/A



 




(ii)


Exercising








Product name,

e.g. call option 


Number of securities


Exercise price per

unit (Note 4)




N/A


N/A


N/A



 




(d)


Other dealings (including transactions in respect of new securities) (Note 3) 








Nature or transaction
(Note 7)


Details


Price per unit

(if applicable) (Note 4)




N/A


N/A


N/A



 




4.


OTHER INFORMATION




 

Agreements, arrangements or understandings relating to options or derivatives 

 



Full details of any agreement, arrangement or understanding between the person

disclosing and any other person relating to the voting rights of any relevant

securities under any option referred to on this form or relating to the voting rights

or future acquisition or disposal of any relevant securities to which any derivative

referred to on this form is referenced. If none, this should be stated. 




None 



 




Is a Supplemental Form 38.5(b) attached? (Note 8)


No




 



Date of disclosure


16/04/2020




Contact name


Tolu Tade




Telephone number


+44207 996 3410




Name of offeree/offeror with which connected 


AbbVie Inc




Nature of connection (Note 9)


Advisor to - AbbVie Inc



 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
ISEFIFIASLIRLII